DAFTAR PUSTAKA

[1] N. I. Girgis, Y. Sultan, Z. Farid et al., “Tuberculous meningitis, Abbassia Fever

Hospital—U.S. Naval Medical Research Unit No. 3—Cairo, Egypt, from 1976
to 1996,” American Journal of Tropical Medicine and Hygiene, vol. 58, no. 1,
pp. 28–34, 1998.
[2] R. B. Rock, S. Hu, G. Gekker et al., “Mycobacterium tubercu-losis-induced
cytokine and chemokine expression by human microglia and astrocytes: effects
of dexamethasone,” Journal of Infectious Diseases, vol. 192, no. 12, pp. 2054–
2058, 2005.
[3] R. Verdon, S. Chevret, J. P. Laissy, and M. Wolff, “Tuberculous meningitis in
adults: review of 48 cases,” Clinical Infectious Diseases, vol. 22, no. 6, pp. 982–
988, 1996.
[4] S. J. Kent, S. M. Crowe, A. Yung, C. R. Lucas, and A. M. Mijch, “Tuberculous
meningitis: a 30-year review,” Clinical Infectious Diseases, vol. 17, no. 6, pp.
987–994, 1993.

[5] C. Bidstrup, P. H. Andersen, P. Skinhøj, and A˚. B. Andersen, “Tuberculous

meningitis in a country with a low incidence of tuberculosis: still a serious
disease and a diagnostic challenge,” Scandinavian Journal of Infectious
Diseases, vol. 34, no. 11, pp. 811–814, 2002.
[6] C. Vinnard, C. A. Winston, E. P. Wileyto, R. R. Macgregor, and G. P. Bisson,
“Isoniazid-resistant tuberculous meningitis, United States, 1993–2005,”
Emerging Infectious Diseases, vol. 17, no. 3, pp. 539–542, 2011.
[7] M. C. Thigpen, C. G. Whitney, N. E. Messonnier et al., “Bac-terial meningitis
in the United States, 1998–2007,” The New England Journal of Medicine, vol.
364, no. 21, pp. 2016–2025, 2011.
[8] A. R. Rich and H. A. McCordock, “The pathogenesis of tuber-culous
meningitis,” Bulletin of the Johns Hopkins Hospital, vol. 52, pp. 5–37, 1933.
[9] J. Berenguer, S. Moreno, F. Laguna et al., “Tuberculous menin-gitis in patients
infected with the human immunodeficiency virus,” The New England Journal
of Medicine, vol. 326, no. 10,
pp. 668–672, 1992.
[10] L. S. Farer, A. M. Lowell, and M. P. Meador, “Extrapulmonary tuberculosis
in the United States,” American Journal of Epi-demiology, vol. 109, no. 2, pp.
205–217, 1979.
[11] J. Keane, S. Gershon, R. P. Wise et al., “Tuberculosis associated with
infliximab, a tumor necrosis factor α-neutralizing agent,” The New England
Journal of Medicine, vol. 345, no. 15, pp. 1098–1104, 2001.
[12] N. J. Farinha, K. A. Razali, H. Holzel, G. Morgan, and V. M. Novelli,
“Tuberculosis of the central nervous system in chil-dren: a 20-year survey,”
Journal of Infection, vol. 41, no. 1, pp. 61–68, 2000.
[13] A. H. Alzeer and J. M. FitzGerald, “Corticosteroids and tuber-culosis: risks
and use as adjunct therapy,” Tubercle and Lung Disease, vol. 74, no. 1, pp. 6–
11, 1993.
[14] M. Henry and R. S. Hlzman, “Tuberculosis of the brain, meninges, and
spinal cord,” in Tuberculosis, W. N. Rom, S. M. Garay et al., Eds., pp. 445–
464, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2nd edition, 2004.
[15] R. Kumar, S. N. Singh, and N. Kohli, “A diagnostic rule for tuberculous
meningitis,” Archives of Disease in Childhood, vol. 81, no. 3, pp. 221–224,
1999.
[16] G. E. Thwaites, T. T. H. Chau, K. Stepniewska et al., “Diagnosis of adult
tuberculous meningitis by use of clinical and labora-tory features,” The Lancet,
vol. 360, no. 9342, pp. 1287–1292, 2002.
[17] M. D. Iseman, A Clinician’s Guide to Tuberculosis, Lippincott Williams &
Wilkins, Baltimore, Md, USA, 1999.
[18] D. H. Kennedy and R. J. Fallon, “Tuberculous meningitis,” Journal of the
American Medical Association, vol. 241, no. 3,
pp. 264–268, 1979.
[19] C. Vinnard, C. A. Winston, E. P. Wileyto, R. R. Macgregor, and G. P.
Bisson, “Isoniazid resistance and death in patients with tuberculous meningitis:
retrospective cohort study,” British Medical Journal, vol. 341, p. c4451, 2010.
[20] E. D. Chan, L. Heifets, and M. D. Iseman, “Immunologic diag-nosis of
tuberculosis: a review,” Tubercle and Lung Disease, vol. 80, no. 3, pp. 131–
140, 2000.
[21] B. K. Gupta, A. Bharat, B. Debapriya, and H. Baruah, “Ad-enosine
deaminase levels in CSF of tuberculous meningitis patients,” Journal of
Clinical Medicine Research, vol. 2, no. 5,
pp. 220–224, 2010.
I. Corral, C. Quereda, E. Navas et al., “Adenosine deaminase activity in
cerebrospinal fluid of HIV-infected patients: limited value for diagnosis of
tuberculous meningitis,” European Jour-nal of Clinical Microbiology and
Infectious Diseases, vol. 23, no. 6, pp. 471–476, 2004.

[23] G. E. Thwaites, M. Caws, T. T. H. Chau et al., “Comparison of conventional

bacteriology with nucleic acid amplification (amplified mycobacterium direct
test) for diagnosis of tuber-culous meningitis before and after inception of
 antituberculo-sis chemotherapy,” Journal of Clinical Microbiology, vol. 42, no.
3, pp. 996–1002, 2004.
[24] M. Pai, L. L. Flores, N. Pai, A. Hubbard, L. W. Riley, and J. M. Colford,
“Diagnostic accuracy of nucleic acid amplification tests for tuberculous
meningitis: a systematic review and meta-analysis,” The Lancet Infectious
Diseases, vol. 3, no. 10, pp. 633– 643, 2003.
[25] V. Jonas, M. J. Alden, J. I. Curry et al., “Detection and iden-tification of
Mycobacterium tuberculosis directly from spu-tum sediments by amplification
of rRNA,” Journal of Clini-cal Microbiology, vol. 31, no. 9, pp. 2410–2416,
1993.
[26] S. Kusum, S. Aman, R. Pallab et al., “Multiplex PCR for rapid diagnosis of
tuberculous meningitis,” Journal of Neurology, vol. 258, no. 10, pp. 1781–
1787, 2011.
[27] J. Dinnes, J. Deeks, H. Kunst et al., “A systematic review of ra-pid
diagnostic tests for the detection of tuberculosis infection,” Health Technology
Assessment, vol. 11, no. 3, pp. 1–196, 2007.
[28] P. R. Donald, T. C. Victor, A. M. Jordaan, J. F. Schoeman, and P. D. van
Helden, “Polymerase chain reaction in the diagnosis of tuberculous
meningitis,” Scandinavian Journal of Infectious Diseases, vol. 25, no. 5, pp.
613–617, 1993.
[29] M. Pienaar, S. Andronikou, and R. van Toorn, “MRI to dem-onstrate
diagnostic features and complications of TBM not seen with CT,” Child’s
Nervous System, vol. 25, no. 8, pp. 941– 947, 2009.
[30] G. Thwaites, M. Fisher, C. Hemingway, G. Scott, T. Solomon, and J. Innes,
“British Infection Society guidelines for the diag-nosis and treatment of
tuberculosis of the central nervous sys-tem in adults and children,” Journal of
Infection, vol. 59, no. 3, pp. 167–187, 2009.
[31] M. Humphries, “The management of tuberculous meningitis,” Thorax, vol.
47, no. 8, pp. 577–581, 1992.
[32] American Thoracic Society, Centers for Disease Control, and Infectious
Diseases Society of America, “Treatment of tuber-culosis,” Morbidity and
Mortality Weekly Report, vol. 52, no. RR-11, pp. 1–77, 2003.
[33] L. M. Mofenson, M. T. Brady, S. P. Danner et al., “Guidelines for the
prevention and treatment of opportunistic infections among HIV-Exposed and
HIV-Infected children: recommen-dations from CDC, the National Institutes of
Health, the HIV Medicine Association of the Infectious Diseases Society of
America, the Pediatric Infectious Diseases Society, and the American Academy
of Pediatrics,” Morbidity and Mortality Weekly Report. Recommendations and
Reports, vol. 58, no. RR-11, pp. 1–166, 2009.
[34] World Health Organization, Treatment of Tuberculosis: Guide-lines, 4th
edition, 2010.
[35] J. P. DeVincenzo, S. E. Berning, C. A. Peloquin, and R. N. Husson,
“Multidrug-resistant tuberculous meningitis: clinical problems and
concentrations of second-line antituberculous medications,” Annals of
Pharmacotherapy, vol. 33, no. 11, pp. 1184–1188, 1999.
[36] J. W. C. Alffenaar, R. van Altena, H. J. Bokkerink¨ et al., “Phar-
macokinetics of moxifloxacin in cerebrospinal fluid and plas-ma in patients
with tuberculous meningitis,” Clinical Infectious Diseases, vol. 49, no. 7, pp.
1080–1082, 2009.
[37] J. J. Kelly, E. A. Horowitz, C. J. Destache, A. H. Fruin, and V. A. Long,
“Diagnosis and treatment of complicated tubercular meningitis,”
Pharmacotherapy, vol. 19, no. 10, pp. 1167–1172, 1999.
[38] G. E. Thwaites, S. M. Bhavnani, T. T. H. Chau et al., “Random-ized
pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for
tuberculous meningitis,” Antimicrobial Agents and Chemotherapy, vol. 55, no.
7, pp. 3244–3253, 2011.
[39] A. Zuger, “Tuberculosis,” in Infections of the Central Nervous System, W.
M. Scheld, R. J. Whitley, and C. M. Marra, Eds., pp. 441–460, Lippincott
Williams & Wilkins, Philadelphia, Pa, USA, 3rd edition, 2004.
[40] G. E. Thwaites, N. T. N. Lan, N. H. Dung et al., “Effect of antituberculosis
drug resistance on response to treatment and outcome in adults with tuberculous
meningitis,” Journal of Infectious Diseases, vol. 192, no. 1, pp. 79–88, 2005.
[41] E. D. Chan, D. Chatterjee, M. D. Iseman, and L. B. Heifets, “Pyrazinamide,
ethambutol, ethionamide, and aminoglyco-sides,” in Tuberculosis, W. N. Rom
and S. M. Garay, Eds., pp. 773–789, Lippincott Williams & Wilkins,
Philadelphia, Pa, USA, 2004.
[42] D. Heemskerk, J. Day, T. T. H. Chau et al., “Intensified treat-ment with high
dose Rifampicin and Levofloxacin compared to standard treatment for adult
patients with tuberculous meningitis (TBM-IT): protocol for a randomized
controlled trial,” Trials, vol. 12, p. 25, 2011.
[43] J. L. Gaillard, C. Silly, A. le Masne et al., “Cerebrospinal fluid penetration
of Amikacin in children with community-ac-quired bacterial meningitis,”
Antimicrobial Agents and Chem-otherapy, vol. 39, no. 1, pp. 253–255, 1995.
[44] P. R. Donald, “Cerebrospinal fluid concentrations of antitu-berculosis
agents in adults and children,” Tuberculosis, vol. 90, no. 5, pp. 279–292, 2010.
[45] A. H. Diacon, A. Pym, M. Grobusch et al., “The diarylquino-line TMC207
for multidrug-resistant tuberculosis,” The New England Journal of Medicine,
vol. 360, no. 23, pp. 2397–2405, 2009.
[46] S. Kaojarern, K. Supmonchai, P. Phuapradit, C. Mokkhavesa, and S.
Krittiyanunt, “Effect of steroids on cerebrospinal fluid penetration of
antituberculous drugs in tuberculous meningi-tis,” Clinical Pharmacology and
Therapeutics, vol. 49, no. 1, pp. 6–12, 1991.
[47] L. Hong, W. Jiang, H. Pan, Y. Jiang, S. Zeng, and W. Zheng, “Brain regional
pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite:
effectiveness in chelating brain manganese,” Drug Metabolism and
Disposition, vol. 39, no. 10, pp. 1904–1909, 2011.
[48] R. Nau, F. Sorgel,¨ and H. Eiffert, “Penetration of drugs through the blood-
cerebrospinal fluid/blood-brain barrier for treat-ment of central nervous system
infections,” Clinical Microbi-ology Reviews, vol. 23, no. 4, pp. 858–883, 2010.
[49] L. J. Strausbaugh, C. D. Mandaleris, and M. A. Sande, “Com-parison of four
aminoglycoside antibiotics in the therapy of experimental E. coli meningitis,”
Journal of Laboratory and Clinical Medicine, vol. 89, no. 4, pp. 692–701, 1977.
[50] A. M. Ginsberg, “Drugs in development for tuberculosis,” Drugs, vol. 70,
no. 17, pp. 2201–2214, 2010.
[51] E. C. Rivers and R. L. Mancera, “New anti-tuberculosis drugs with novel
mechanisms of action,” Current Medicinal Chem-istry, vol. 15, no. 19, pp.
1956–1967, 2008.
[52] C. C. Leung, T. H. Lam, W. M. Chan et al., “Diabetic control and risk of
tuberculosis: a cohort study,” American Journal of Epidemiology, vol. 167, no.
12, pp. 1486–1494, 2008.
[53] J. de Gans and D. van Beek, “Dexamethasone in adults with
bacterial meningitis,” The New England Journal of Medicine, vol. 347, no. 20,
pp. 1549–1556, 2002.

[54] T. H. Nguyen, T. H. Tran, G. Thwaites et al., “Dexamethasone in

Vietnamese adolescents and adults with bacterial meningi-tis,” The New
England Journal of Medicine, vol. 357, no. 24, pp. 2431–2440, 2007.

[55] M. C. Brouwer, P. McIntyre, J. de Gans, K. Prasad, and D. van de

Beek, “Corticosteroids for acute bacterial meningitis,” Co-chrane Database of
Systematic Reviews, vol. 9, Article ID CD004405, 2010.

[56] H. Spapen, G. van Berlaer, M. Moens, and I. Hubloue, “Ad-junctive

steroid treatment in acute bacterial meningitis. “To do or not to do: that is the
question”,” Acta Clinica Belgica, vol. 66, no. 1, pp. 42–45, 2011.

[57] K. Prasad and M. B. Singh, “Corticosteroids for managing

tuberculous meningitis,” Cochrane Database of Systematic Re-views, no. 1, p.
CD002244, 2008.

[58] G. E. Thwaites, D. B. Nguyen, H. D. Nguyen et al., “Dex-

amethasone for the treatment of tuberculous meningitis in adolescents and
adults,” The New England Journal of Medicine, vol. 351, no. 17, pp. 1741–
1751, 2004.

[59] N. I. Girgis, Z. Farid, M. E. Kilpatrick, Y. Sultan, and I. A. Mikhail,

“Dexamethasone adjunctive treatment for tubercu-lous meningitis,” Pediatric
Infectious Disease Journal, vol. 10, no. 3, pp. 179–183, 1991.
[60] M. Curto, C. Reali, G. Palmieri et al., “Inhibition of cytokines
expression in human microglia infected by virulent and non-virulent
mycobacteria,” Neurochemistry International, vol. 44, no. 6, pp. 381–392,
2004.

[61] C. M. Mastroianni, F. Paoletti, M. Lichtner, C. D’Agostino, V.

Vullo, and S. Delia, “Cerebrospinal fluid cytokines in pa-tients with
tuberculous meningitis,” Clinical Immunology and Immunopathology, vol. 84,
no. 2, pp. 171–176, 1997.

[62] L. Tsenova, K. Sokol, V. H. Freedman, and G. Kaplan, “A com-

bination of thalidomide plus antibiotics protects rabbits from mycobacterial
meningitis-associated death,” Journal of Infec-tious Diseases, vol. 177, no. 6,
pp. 1563–1572, 1998.

[63] L. Tsenova, A. Bergtold, V. H. Freedman, R. A. Young, and G.

Kaplan, “Tumor necrosis factor α is a determinant of patho-genesis and disease
progression in mycobacterial infection in the central nervous system,”
Proceedings of the National Acad-emy of Sciences of the United States of
America, vol. 96, no. 10, pp. 5657–5662, 1999.

[64] K. Møller, F. S. Larsen, P. Bie, and P. Skinhøj, “The syndrome of

inappropriate secretion of antidiuretic hormone and fluid restriction in
meningitis—how strong is the evidence?” Scan-dinavian Journal of Infectious
Diseases, vol. 33, no. 1, pp. 13–26, 2001.

[65] M. Gelabert and M. Castro-Gago, “Hydrocephalus and tuber-culous

meningitis in children. Report on 26 cases,” Child’s Nervous System, vol. 4,
no. 5, pp. 268–270, 1988.

[66] W. C. Clark, J. C. Metcalf Jr., M. S. Muhlbauer, F. C. Dohan Jr., and

J. H. Robertson, “Mycobacterium tuberculosis meningitis: a report of twelve
cases and a literature review,” Neurosurgery, vol. 18, no. 5, pp. 604–610, 1986.

[67] A. P. Chugh, M. Husain, R. K. Gupta, B. K. Ojha, A. Chandra, and

M. Rastogi, “Surgical outcome of tuberculous meningitis hydrocephalus treated
by endoscopic third ventriculostomy: prognostic factors and postoperative
neuroimaging for func-tional assessment of ventriculostomy,” Journal of
Neurosurgery:
Pediatrics, vol. 3, no. 5, pp. 371–377, 2009.
¨ ¨
[68] S. Kemaloglu, U. Ozkan, Y. Bukte, A. Ceviz, and M. Ozates,
“Timing of shunt surgery in childhood tuberculous meningitis
with hydrocephalus,” Pediatric Neurosurgery, vol. 37, no. 4, pp.

194–198, 2002.

[69] D. Lamprecht, J. Schoeman, P. Donald, and H. Hartzenberg,

“Ventriculoperitoneal shunting in childhood tuberculous meningitis,” British
Journal of Neurosurgery, vol. 15, no. 2, pp. 119–125, 2001.

[70] U. Srikantha, J. V. Morab, S. Sastry et al., “Outcome of ven-

triculoperitoneal shunt placement in Grade IV tubercular meningitis with
hydrocephalus: a retrospective analysis in 95 patients,” Journal of
Neurosurgery: Pediatrics, vol. 4, no. 2, pp. 176–183, 2009.

[71] R. K. Garg and M. K. Sinha, “Tuberculous meningitis in pa-tients

infected with human immunodeficiency virus,” Journal of Neurology, vol. 258,
no. 1, pp. 3–13, 2011.

[72] V. Asselman, F. Thienemann, D. J. Pepper et al., “Central nervous

system disorders after starting antiretroviral therapy in South Africa,” AIDS,
vol. 24, no. 18, pp. 2871–2876, 2010.

[73] N. Valin, J. Pacanowski, L. Denoeud et al., “Risk factors for

’unmasking immune reconstitution inflammatory syndrome’ presentation of
tuberculosis following combination antiretro-viral therapy initiation in HIV-
infected patients,” AIDS, vol. 24, no. 10, pp. 1519–1525, 2010.

[74] M. E. Tor¨ok,¨ N. T. B. Yen, T. T. H. Chau et al., “Timing of ini-

tiation of antiretroviral therapy in human immunodeficiency virus (HIV)-
associated tuberculous meningitis,” Clinical Infec-tious Diseases, vol. 52, no.
11, pp. 1374–1383, 2011.

[75] S. S. Abdool Karim, K. Naidoo, A. Grobler et al., “Timing of

initiation of antiretroviral drugs during tuberculosis therapy,” The New
England Journal of Medicine, vol. 362, no. 8, pp. 697– 706, 2010.

[76] J. E. Kaplan, C. Benson, K. H. Holmes, J. T. Brooks, A. Pau, and H.

Masur, “Guidelines for prevention and treatment of opportunistic infections in
HIV-infected adults and adoles-cents: recommendations from CDC, the
National Institutes of Health, and the HIV Medicine Association of the
Infectious Diseases Society of America,” Morbidity and Mortality Weekly
Report. Recommendations and Reports, vol. 58, no. RR-4, pp. 1–207, 2009.
[77] M. Caws, G. Thwaites, K. Stepniewska et al., “Beijing genotype of
Mycobacterium tuberculosis is significantly associated with human
immunodeficiency virus infection and multidrug re-sistance in cases of
tuberculous meningitis,” Journal of Clinical Microbiology, vol. 44, no. 11, pp.
3934–3939, 2006.

[78] D. Cecchini, J. Ambrosioni, C. Brezzo et al., “Tuberculous

meningitis in HIV-infected patients: drug susceptibility and clinical outcome,”
AIDS, vol. 21, no. 3, pp. 373–374, 2007.

[79] V. B. Patel, N. Padayatchi, A. I. Bhigjee et al., “Multidrug-resis-tant

tuberculous meningitis in KwaZulu-Natal, South Africa,” Clinical Infectious
Diseases, vol. 38, no. 6, pp. 851–856, 2004.

[80] M. E. Torok, T. T. H. Chau, P. P. Mai et al., “Clinical and

microbiological features of HIV-associated tuberculous men-ingitis in
Vietnamese adults,” PLoS ONE, vol. 3, no. 3, Article ID e1772, 2008.

[81] F. A. Khan, J. Minion, M. Pai et al., “Treatment of active

tuberculosis in HIV-coinfected patients: a systematic review and meta-
analysis,” Clinical Infectious Diseases, vol. 50, no. 9, pp. 1288–1299, 2010.

[82] M. A. de Groote, J. C. Gilliland, C. L. Wells et al., “Comparative

studies evaluating mouse models used for efficacy testing of experimental drugs
against Mycobacterium tuberculosis,” An-timicrobial Agents and
Chemotherapy, vol. 55, no. 3, pp. 1237– 1247, 2011.
[83] L. Tsenova, R. Harbacheuski, A. L. Moreira et al., “Evaluation of
the Mtb72F polyprotein vaccine in a rabbit model of tuber-culous meningitis,”
Infection and Immunity, vol. 74, no. 4, pp. 2392–2401, 2006.

[84] L. Tsenova, R. Harbacheuski, N. Sung, E. Ellison, D. Fallows, and

G. Kaplan, “BCG vaccination confers poor protection against M. tuberculosis
HN878-induced central nervous sys-tem disease,” Vaccine, vol. 25, no. 28, pp.
5126–5132, 2007.

[85] G. T. J. van Well, C. W. Wieland, S. Florquin, J. J. Roord, T. van

der Poll, and A. M. van Furth, “A new murine model to study the pathogenesis
of tuberculous meningitis,” Journal of Infec-tious Diseases, vol. 195, no. 5, pp.
694–697, 2007.

[86] I. M. Orme, “The search for new vaccines against tuberculo-sis,”

Journal of Leukocyte Biology, vol. 70, no. 1, pp. 1–10, 2001.
[87] P. E. M. Fine, “BCG: the challenge continues,” Scandinavian
Journal of Infectious Diseases, vol. 33, no. 4, pp. 243–245, 2001.

[88] L. C. Rodrigues, V. K. Diwan, and J. G. Wheeler, “Protective effect

of BCG against tuberculous meningitis and miliary tu-berculosis: a meta-
analysis,” International Journal of Epidemi-ology, vol. 22, no. 6, pp. 1154–
1158, 1993.